Pharmacokinetics of lidocaine delivered from a transmucosal patch in children.

Andrea Leopold, Stephen Wilson, Joel S. Weaver, Amr Moursi

Research output: Contribution to journalArticle

Abstract

The DentiPatch lidocaine transoral delivery system (Noven Pharmaceuticals) is indicated for mild topical anesthesia of mucosal membranes in the mouth. The DentiPatch is a mucoadhesive patch containing 46.1 mg of lidocaine (20% concentration). Current studies in adults report that DentiPatch application produces very low plasma concentrations of lidocaine. However, it is not known what plasma levels are obtained when the same dosage is used in children. The purpose of this study was to determine whether the plasma lidocaine concentrations generated by the DentiPatch are within a safe range for children. The sample in this study was 11 children aged 2-7 years requiring general anesthesia for comprehensive dental care. A lidocaine DentiPatch was placed on the buccal mucosa above the maxillary incisors for 5 minutes. Blood samples were drawn before placing the DentiPatch and at various time intervals after removing it. Blood samples were analyzed by fluorescence polarization immunoassay to determine the plasma concentrations of lidocaine and its major metabolite, monoethylglycinexylidide. The lidocaine and monoethylglycinexylidide absorbed from the DentiPatch did not reach toxic plasma levels in children. However, plasma concentrations were much higher than in adults and were high enough to require inclusion in the calculation of total lidocaine administered to a pediatric patient.

Original languageEnglish (US)
Pages (from-to)82-87
Number of pages6
JournalAnesthesia Progress
Volume49
Issue number3
StatePublished - Jun 2002

Fingerprint

Lidocaine
Pharmacokinetics
monoethylglycinexylidide
Comprehensive Dental Care
Fluorescence Polarization Immunoassay
Poisons
Mouth Mucosa
Incisor
General Anesthesia
Mouth
Anesthesia
Pediatrics
Membranes
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Anesthesiology and Pain Medicine

Cite this

Pharmacokinetics of lidocaine delivered from a transmucosal patch in children. / Leopold, Andrea; Wilson, Stephen; Weaver, Joel S.; Moursi, Amr.

In: Anesthesia Progress, Vol. 49, No. 3, 06.2002, p. 82-87.

Research output: Contribution to journalArticle

Leopold, Andrea ; Wilson, Stephen ; Weaver, Joel S. ; Moursi, Amr. / Pharmacokinetics of lidocaine delivered from a transmucosal patch in children. In: Anesthesia Progress. 2002 ; Vol. 49, No. 3. pp. 82-87.
@article{aab3f5c4e55e4bc9b0160735e9e24d03,
title = "Pharmacokinetics of lidocaine delivered from a transmucosal patch in children.",
abstract = "The DentiPatch lidocaine transoral delivery system (Noven Pharmaceuticals) is indicated for mild topical anesthesia of mucosal membranes in the mouth. The DentiPatch is a mucoadhesive patch containing 46.1 mg of lidocaine (20{\%} concentration). Current studies in adults report that DentiPatch application produces very low plasma concentrations of lidocaine. However, it is not known what plasma levels are obtained when the same dosage is used in children. The purpose of this study was to determine whether the plasma lidocaine concentrations generated by the DentiPatch are within a safe range for children. The sample in this study was 11 children aged 2-7 years requiring general anesthesia for comprehensive dental care. A lidocaine DentiPatch was placed on the buccal mucosa above the maxillary incisors for 5 minutes. Blood samples were drawn before placing the DentiPatch and at various time intervals after removing it. Blood samples were analyzed by fluorescence polarization immunoassay to determine the plasma concentrations of lidocaine and its major metabolite, monoethylglycinexylidide. The lidocaine and monoethylglycinexylidide absorbed from the DentiPatch did not reach toxic plasma levels in children. However, plasma concentrations were much higher than in adults and were high enough to require inclusion in the calculation of total lidocaine administered to a pediatric patient.",
author = "Andrea Leopold and Stephen Wilson and Weaver, {Joel S.} and Amr Moursi",
year = "2002",
month = "6",
language = "English (US)",
volume = "49",
pages = "82--87",
journal = "Anesthesia Progress",
issn = "0003-3006",
publisher = "Allen Press Inc.",
number = "3",

}

TY - JOUR

T1 - Pharmacokinetics of lidocaine delivered from a transmucosal patch in children.

AU - Leopold, Andrea

AU - Wilson, Stephen

AU - Weaver, Joel S.

AU - Moursi, Amr

PY - 2002/6

Y1 - 2002/6

N2 - The DentiPatch lidocaine transoral delivery system (Noven Pharmaceuticals) is indicated for mild topical anesthesia of mucosal membranes in the mouth. The DentiPatch is a mucoadhesive patch containing 46.1 mg of lidocaine (20% concentration). Current studies in adults report that DentiPatch application produces very low plasma concentrations of lidocaine. However, it is not known what plasma levels are obtained when the same dosage is used in children. The purpose of this study was to determine whether the plasma lidocaine concentrations generated by the DentiPatch are within a safe range for children. The sample in this study was 11 children aged 2-7 years requiring general anesthesia for comprehensive dental care. A lidocaine DentiPatch was placed on the buccal mucosa above the maxillary incisors for 5 minutes. Blood samples were drawn before placing the DentiPatch and at various time intervals after removing it. Blood samples were analyzed by fluorescence polarization immunoassay to determine the plasma concentrations of lidocaine and its major metabolite, monoethylglycinexylidide. The lidocaine and monoethylglycinexylidide absorbed from the DentiPatch did not reach toxic plasma levels in children. However, plasma concentrations were much higher than in adults and were high enough to require inclusion in the calculation of total lidocaine administered to a pediatric patient.

AB - The DentiPatch lidocaine transoral delivery system (Noven Pharmaceuticals) is indicated for mild topical anesthesia of mucosal membranes in the mouth. The DentiPatch is a mucoadhesive patch containing 46.1 mg of lidocaine (20% concentration). Current studies in adults report that DentiPatch application produces very low plasma concentrations of lidocaine. However, it is not known what plasma levels are obtained when the same dosage is used in children. The purpose of this study was to determine whether the plasma lidocaine concentrations generated by the DentiPatch are within a safe range for children. The sample in this study was 11 children aged 2-7 years requiring general anesthesia for comprehensive dental care. A lidocaine DentiPatch was placed on the buccal mucosa above the maxillary incisors for 5 minutes. Blood samples were drawn before placing the DentiPatch and at various time intervals after removing it. Blood samples were analyzed by fluorescence polarization immunoassay to determine the plasma concentrations of lidocaine and its major metabolite, monoethylglycinexylidide. The lidocaine and monoethylglycinexylidide absorbed from the DentiPatch did not reach toxic plasma levels in children. However, plasma concentrations were much higher than in adults and were high enough to require inclusion in the calculation of total lidocaine administered to a pediatric patient.

UR - http://www.scopus.com/inward/record.url?scp=4644302317&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=4644302317&partnerID=8YFLogxK

M3 - Article

VL - 49

SP - 82

EP - 87

JO - Anesthesia Progress

JF - Anesthesia Progress

SN - 0003-3006

IS - 3

ER -